...Thank you, Olivia, and thanks to those of you attending today's quarterly call. Dr. Shai Gozani, President and CEO of NeuroMetrix, will be participating in the call also. By way of background, we are a Boston-based medical technology company with a mission to reduce the impact of neurological disorders and pain syndromes on individuals and on population health. Our technologies are noninvasive, and we hold extensive proprietary intellectual property. Our business model is one of recurring revenue from an installed customer base, and our principal products are DPNCheck, a diagnostic technology providing rapid point-of-care detection of peripheral neuropathy, and Quell, an over-the-counter wearable neurostimulation technology that is indicated for symptomatic relief of lower extremity chronic pain. Revenues in our first quarter of 2022 were $2.3 million, up 6.8% from Q1 of last year. On a sequential basis, revenues increased by 26.5% from Q4 2021. DPNCheck contributes the majority of our...
